{
  "meta": {
    "timestamp": "2025-01-06T09:37:13.775672",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "ASTELLAS PHARMA NPV",
      "symbol": "ALPMY",
      "analysis": {
        "historical": {
          "risk_score": 60,
          "key_risks": [
            "Regulatory challenges including delays or rejections in drug approvals",
            "Pricing pressures due to increasing scrutiny on drug pricing",
            "Patent expirations leading to generic competition",
            "Clinical trial setbacks impacting investor confidence",
            "Product recalls damaging reputation and leading to regulatory penalties"
          ],
          "controversies": [
            "FDA denial of approval for gastric cancer drug",
            "Narrow avoidance of Medicare price negotiation for Xtandi",
            "Product recalls due to empty capsules and ingredient concerns"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical scrutiny regarding drug pricing",
            "Addressing unmet medical needs with products like Veozah"
          ],
          "governance_issues": [
            "Regulatory scrutiny across multiple markets",
            "Costs associated with strategic acquisitions impacting profits"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Regulatory Science | Astellas Pharma Inc.",
              "snippet": "Pharmaceutical companies interact with regulatory authorities throughout a drug lifecycle, from the time before first-in-human clinical trials to post-marketing. We provide documented data from non-clinical studies to demonstrate the safety and efficacy for the drug candidate or product based on scientific evidence.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408549+00:00",
              "published_date": null,
              "source_hash": "37fab501d6348ca46625288b767c9d5f"
            },
            {
              "url": "",
              "title": " Astellas' Corporate-wide Digital Transformation Driven by Analytics",
              "snippet": "Astellas Pharma Inc. March 27, 2023. Cautionary Statement Regarding Forward-Looking Information 2 ... investigational compounds will receive regulatory approval or become commercially available for the uses being investigated. ... Phases of Clinical Trials, NDA: New Drug Application, NPV: Net Present Value",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408572+00:00",
              "published_date": null,
              "source_hash": "e7b2d2b2d7a2839cd0fc157eebc13ab0"
            },
            {
              "url": "",
              "title": "Q&A from the 19th Annual Shareholders Meeting - Astellas Pharma",
              "snippet": "Pharmaceuticals are manufactured using manufacturing methods that have been reviewed and approved by regulatory authorities, and we guarantee that the processes and quality are properly controlled for each production lot. ... Q8 The current management structure is facing significant challenges in terms of market research, market expansion ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408578+00:00",
              "published_date": null,
              "source_hash": "31ca9cd0141cea7ef6cea08e22e739af"
            },
            {
              "url": "",
              "title": "Global impact: How regulatory affairs is shaping development of cutting ...",
              "snippet": "Regulatory affairs as a function has undergone a significant shift in its strategic role and impact over the past 10 years - delivering value from early-development through to the management of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408583+00:00",
              "published_date": null,
              "source_hash": "0e4530c67c74d8ff23e5e2cfbca4a361"
            },
            {
              "url": "",
              "title": "Astellas pulls geographic atrophy drug filing in the EU",
              "snippet": "Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408588+00:00",
              "published_date": null,
              "source_hash": "3b1b31e6f1465df728a3b7450dcef231"
            },
            {
              "url": "",
              "title": "Astellas' VYLOY\u2122 (zolbetuximab-clzb) Approved by U.S. FDA for Treatment ...",
              "snippet": "VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive . TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408597+00:00",
              "published_date": null,
              "source_hash": "d9e46cbaefed016d3652459d2484a620"
            },
            {
              "url": "",
              "title": "Astellas' new CEO Naoki Okamura takes over a company in transition",
              "snippet": "Including regulatory and commercial milestones, Astellas paid a mere $765 million for a drug that generated $5.9 billion in worldwide sales last year, with $4.7 billion of that rung up by Astellas ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408610+00:00",
              "published_date": null,
              "source_hash": "b591474340c323752e0ecc2c53a4f8ba"
            },
            {
              "url": "",
              "title": "Astellas Pharma, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap",
              "snippet": "There are no currently approved treatments for GA secondary to AMD outside the US, where ACP was approved under the name IZERVAY in August 2023. Astellas will work with regulatory authorities to explore all available options to make ACP accessible to patients with GA globally, including those in Europe.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408614+00:00",
              "published_date": null,
              "source_hash": "4aae53804611931372cd422368e2ebb6"
            },
            {
              "url": "",
              "title": "FDA approves Astellas' VYLOY for gastric cancer treatment",
              "snippet": "Astellas Pharma has gained approval from the US Food and Drug Administration (FDA) for VYLOY (zolbetuximab-clzb), in conjunction with chemotherapy, for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancer.. This is the first US approval for VYLOY, a therapy targeting claudin (CLDN)-18.2-positive tumours identified through an FDA-approved diagnostic assay, Roche's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408618+00:00",
              "published_date": null,
              "source_hash": "a72301b6eb58810a6d634e0aed61155d"
            },
            {
              "url": "",
              "title": "Jobs - Astellas Pharmaceutical",
              "snippet": "Every day, we are driven to develop and deliver innovative and effective new medicines to patients and physicians. If you want to be part of this exciting work, you belong at Astellas! Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:44.408622+00:00",
              "published_date": null,
              "source_hash": "75bf678a880781526aac2ab422bd0930"
            },
            {
              "url": "",
              "title": "FDA denies approval of Astellas gastric cancer drug",
              "snippet": "Japanese drugmaker Astellas Pharma (OTCPK:ALPMY) said on Monday that the U.S. Food and Drug Administration (FDA ... Besides the U.S., regulatory applications are also under review in several ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:46.692911+00:00",
              "published_date": "2024-01-09T10:53:00+00:00",
              "source_hash": "c8215a996bd0c7eb72f21aa627f2dcf4"
            },
            {
              "url": "",
              "title": "Astellas, Endo issue US drug recalls over empty capsule, ingredient concerns",
              "snippet": "Astellas Pharma and Endo subsidiary Endo USA issued ... The product, which predates the Federal Food, Drug and Cosmetic Act of 1938, has never been submitted to the agency for review and is ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:54.672633+00:00",
              "published_date": "2025-01-03T09:19:00+00:00",
              "source_hash": "c537b1ba2d4bbf0044aca42b6d789ac7"
            },
            {
              "url": "",
              "title": "Astellas Pharma's Veozah gets Health Canada approval as first and only non-hormonal treatment for VMS associated with menopause",
              "snippet": "Astellas Pharma Canada ... Health Canada's approval of Veozah follows approvals in the United States (US), United Kingdom (UK), Australia and Europe. Regulatory approvals are based on the results of the BRIGHT SKY programme, which included three phase ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:46.692944+00:00",
              "published_date": "2024-12-05T09:00:00+00:00",
              "source_hash": "1e38a09774c98d60e349452e5c97e49e"
            },
            {
              "url": "",
              "title": "Astellas nabs lead in claudin 18.2 after positive stomach cancer trial",
              "snippet": "Astellas Pharma's zolbetuximab - currently leading an expanding pack of drugs targeting claudin ... could result in regulatory filings later in 2023, putting Astellas on course to become the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:46.692951+00:00",
              "published_date": "2023-02-04T16:32:00+00:00",
              "source_hash": "85282c5b64719505b0149aa983728d3a"
            },
            {
              "url": "",
              "title": "Axcelead DDP inks drug discovery service agreement with Astellas for targeted protein degraders",
              "snippet": "Axcelead Drug Discovery Partners, Inc. announced that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. to explore new ... called DegLead Platform to solve various challenges in targeted protein degrader discovery, including ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T16:36:46.692957+00:00",
              "published_date": "2024-12-27T08:59:00+00:00",
              "source_hash": "b100c7e2077348a04e0f994841d1fa3d"
            },
            {
              "url": "",
              "title": " Astellas' Corporate-wide Digital Transformation Driven by Analytics",
              "snippet": "Astellas Pharma Inc. March 27, 2023. Cautionary Statement Regarding Forward-Looking Information 2 ... Patent expiration Pipeline D/EBITDA Operating CF/D Cash/D Financial policy Company A Company B ty Therapeutic Area ... the occurrence or non-occurrence of the uncertainty factor and the amplitude of its impact. NPV: Net Present Value",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468409+00:00",
              "published_date": null,
              "source_hash": "83d565729477b3d8c593dabfe66a9ee5"
            },
            {
              "url": "",
              "title": "Financial Information | Astellas Pharma Inc.",
              "snippet": "You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468560+00:00",
              "published_date": null,
              "source_hash": "16a6a1408ab6fde3acafa72908677b76"
            },
            {
              "url": "",
              "title": "Earnings call: Astellas Pharma exceeds revenue forecast, faces profit ...",
              "snippet": "Astellas Pharma's full-year revenue increased by 5.6% to JPY 1,603.7 billion. Core operating profit dropped by 35.6% to JPY 184.6 billion due to costs associated with the Iveric Bio acquisition.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468573+00:00",
              "published_date": null,
              "source_hash": "c5e7f6d077db80b1ccf930e606d50457"
            },
            {
              "url": "",
              "title": "Corporate Strategic Plan 2021 | Astellas Pharma Inc.",
              "snippet": "R&D is underway to build a new Post-PoC portfolio from these areas by the end of FY2025. We expect that sales of Strategic products such as PADCEV \u00ae and fezolinetant will offset the decline of XTANDI \u00ae sales, for which the patent will expire after 2027, and that the projects arising from the Focus Area approach will be further growth drivers ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468583+00:00",
              "published_date": null,
              "source_hash": "9cb8ba44c2e8d7d92f85ee1fe7213e9c"
            },
            {
              "url": "",
              "title": "Astellas hit by US patent verdict for incontinence drug",
              "snippet": "The case - heard in a Delaware district court - was focused on US Patent No. 10,842,780 covering extended-release formulations of mirabegron that isn't due to expire until 2030.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468596+00:00",
              "published_date": null,
              "source_hash": "dc68e13765e07fd936ae5be64e95b5d7"
            },
            {
              "url": "",
              "title": "Astellas loses patent on key drug, outlook unclear | Reuters",
              "snippet": "Japan's Astellas Pharma  loses U.S. patent protection on Prograf, a major transplant drug, on Tuesday, amid worries that its market share may erode more quickly than expected despite only ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468604+00:00",
              "published_date": null,
              "source_hash": "b7662b2ff1ef3ccbb35c226c1b53936e"
            },
            {
              "url": "",
              "title": "Patents Assigned to Astellas Pharma Inc ... - Justia Patents Search",
              "snippet": "Patents Assigned to Astellas Pharma Inc. Pharmaceutical composition. Patent number: 12178814 Abstract: Provided is a pharmaceutical composition containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof and a sweetener for reducing ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468615+00:00",
              "published_date": null,
              "source_hash": "06a12b27c36b3ed73239d07b37ff424f"
            },
            {
              "url": "",
              "title": "Astellas Pharma sees highest patent filings and grants during April in ...",
              "snippet": "Astellas Pharma saw the highest growth of 1.31% in patent filings in May and 0.86% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.6% and grants by 0.86%. GlobalData's DataBook provides a comprehensive analysis of Astellas Pharma's patent filings and grants. Buy the databook here.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468622+00:00",
              "published_date": null,
              "source_hash": "4892ae66de242ccbecaf7ca66b71d46c"
            },
            {
              "url": "",
              "title": "Astellas case highlights patent eligibility under Section 101 and the ...",
              "snippet": "In Astellas Pharma Inc. v. Sandoz Inc., the US Court of Appeals for the Federal Circuit vacated a sua sponte district court ruling that found Astellas's asserted patent ineligible under Title 35 of the US Code, Section 101. The Federal Circuit decision affirmed the applicability of the party presentation principle with respect to issues of patent eligibility under Section 101; as with other ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468635+00:00",
              "published_date": null,
              "source_hash": "c2955ade6723852b23b2edd26fcea846"
            },
            {
              "url": "",
              "title": "Top 50 Pharma: Oncology patent leaders 2024 - drugdiscoverytrends.com",
              "snippet": "Explore the full analysis of patent leaders, market impact, and R&D efficiency. Drug Discovery and Development. ... Swiss pharma giants Novartis and Roche consistently rank among the top pharma companies in terms of revenue. In 2024, the two companies are also leading in total international patent volume. ... Astellas Pharma: 20,979,605,504 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations revenue impact",
              "retrieved_at": "2025-01-06T16:36:48.468644+00:00",
              "published_date": null,
              "source_hash": "6c609a8a859bb20e19b47976810f57f3"
            },
            {
              "url": "",
              "title": "Astellas pulls IRA lawsuit after avoiding CMS negotiation list",
              "snippet": "When CMS last week revealed its list of the first 10 drugs eligible for Medicare price negotiations, Astellas' Xtandi did not make the cut. This surprised some pharma watchers, who had expected ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.303892+00:00",
              "published_date": null,
              "source_hash": "eceae5fee5a7abacfb9bfcad886ab529"
            },
            {
              "url": "",
              "title": "Financial Information | Astellas Pharma Inc.",
              "snippet": "Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.303997+00:00",
              "published_date": null,
              "source_hash": "469b38bff995ec6b1cdb48151505df57"
            },
            {
              "url": "",
              "title": "Investor Relations | Astellas Pharma Inc.",
              "snippet": "In Japanese pharmaceutical market, 90% of which is accounted for by prescription drugs. Prescription drugs are divided into two categories: Brand name and generic drugs. Brand name drugs are developed with new active pharmaceutical ingredients or for new purposes, and then manufactured and marketed in house.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304013+00:00",
              "published_date": null,
              "source_hash": "f0ca31c8a572fc9394da3cfba4ce792a"
            },
            {
              "url": "",
              "title": "Astellas Pharma Revenue - Stock Analysis",
              "snippet": "Astellas Pharma had revenue of 462.50B JPY in the quarter ending September 30, 2024, with 17.94% growth. This brings the company's revenue in the last twelve months to 1.77T, up 16.32% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304024+00:00",
              "published_date": null,
              "source_hash": "f300332272c718761914024a418ebe46"
            },
            {
              "url": "",
              "title": "Astellas Pharma Inc. company profile - Statista",
              "snippet": "In 2022 the revenue of Astellas Pharma Inc. grew by 14.7%, reaching an all-time high. ... EU-ETS allowance prices in the European Union 2022-2024; Renewable energy capacity 2023 by country; Topics ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304034+00:00",
              "published_date": null,
              "source_hash": "cfab58cb0bfbe27c1f1be6080dc28ca6"
            },
            {
              "url": "",
              "title": "Astellas Pharma - Funding, Financials, Valuation & Investors - Crunchbase",
              "snippet": "Astellas Pharma has raised 1 round. This was a Grant round raised on Jul 22, 2020. Astellas Pharma is registered under the ticker OTCPINK:ALPMY . Astellas Pharma is funded by National Institute on Drug Abuse (NIDA). Astellas Pharma has made 11 investments. Their most recent investment was on Oct 8, 2024, when AviadoBio raised",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304043+00:00",
              "published_date": null,
              "source_hash": "697a780ed3a959b7b96727970060ceba"
            },
            {
              "url": "",
              "title": "Astellas Pharma Statistics - Stock Analysis",
              "snippet": "Detailed statistics for Astellas Pharma Inc. (ALPMY) stock, including valuation metrics, financial numbers, share information and more. ... The beta is 0.29, so Astellas Pharma's price volatility has been lower than the market average. Beta (5Y) 0.29: 52-Week Price Change -13.56%: 50-Day Moving Average : 10.96: 200-Day Moving Average : 10.78 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304053+00:00",
              "published_date": null,
              "source_hash": "7568fb192964697f338996c5f007c922"
            },
            {
              "url": "",
              "title": "Astellas Pharma, Inc. Company Profile & Data: stocks, market cap ...",
              "snippet": "Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. Top 1-year algo backtest: +265.99% $10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304062+00:00",
              "published_date": null,
              "source_hash": "0fd509f3dc3bae67495ced71d30a3b55"
            },
            {
              "url": "",
              "title": "Astellas Pharma Inc.: Financial Data Forecasts Estimates and ...",
              "snippet": "Astellas Pharma Inc.: Forcasts, revenue, earnings, analysts expectations, ratios for Astellas Pharma Inc. Stock | YPH | JP3942400007",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304071+00:00",
              "published_date": null,
              "source_hash": "f2a71bc567d9ae823a2f0cd37a50041c"
            },
            {
              "url": "",
              "title": "Astellas Pharma - Financials, Funding, Investors, Acquisitions - ZoomInfo",
              "snippet": "Astellas Pharma has recently completed 3 funding rounds: Stock Issuance/Offering on Jul 20, 2016, Series C on Oct 13, 2015, Series B on Dec 2, 2014. What is the total amount of funding Astellas Pharma has raised to date?",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:52.304079+00:00",
              "published_date": null,
              "source_hash": "3538b2d50021c76157c0c77d3869fdc9"
            },
            {
              "url": "",
              "title": "Astellas builds case for menopause drug fezolinetant",
              "snippet": "New data for Astellas Pharma's non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts to roll out in the US ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:54.672684+00:00",
              "published_date": "2023-11-29T23:59:00+00:00",
              "source_hash": "15271ebd1ecb8fc60e510cfeec56ae0f"
            },
            {
              "url": "",
              "title": "Astellas cuts $795m deal with Pandion for type 1 diabetes drugs",
              "snippet": "Astellas Pharma is boosting its early-stage pipeline ... Under the terms of the deal, Pandion will come up with multiple bispecific drug candidates designed to tackle the autoimmune reaction ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:54.672698+00:00",
              "published_date": "2019-10-31T00:00:00+00:00",
              "source_hash": "048e60f342739ec6dba7379ca729a308"
            },
            {
              "url": "",
              "title": "FDA denies approval of Astellas gastric cancer drug",
              "snippet": "Japanese drugmaker Astellas Pharma (OTCPK:ALPMY) said on Monday that the U.S. Food and Drug Administration (FDA) has declined to approve the biologics license application of its experimental ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:54.672709+00:00",
              "published_date": "2024-01-09T10:53:00+00:00",
              "source_hash": "b6257dac62b2a166bdcc5f0d53b9df39"
            },
            {
              "url": "",
              "title": "Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders",
              "snippet": "\"Axcelead DDP\") announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Chuo-Ku, Tokyo, Japan; \"Astellas\") to explore new candidate compounds ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV drug pricing controversies",
              "retrieved_at": "2025-01-06T16:36:54.672740+00:00",
              "published_date": "2024-12-25T23:59:00+00:00",
              "source_hash": "facff2f080acfa2de1832d0e5bf37a62"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "ASTELLAS PHARMA NPV regulatory challenges drug approvals",
              "rationale": "Investigate delays or rejections in drug approvals impacting revenue",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "ASTELLAS PHARMA NPV patent expirations revenue impact",
              "rationale": "Assess the financial impact of losing exclusivity for key products",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "ASTELLAS PHARMA NPV drug pricing controversies",
              "rationale": "Examine public and regulatory scrutiny on drug pricing practices",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T09:37:13.775691",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}